Navigation Links
Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
Date:7/31/2009

SAN CARLOS, Calif., July 31 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) is scheduled to present at the upcoming BMO Capital Markets 9th Annual Focus on Healthcare Conference at the Millennium Broadway Hotel in New York City on Wednesday, August 5, 2009 at 1:45 p.m. Eastern time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until August 31, 2009.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own potentially high-value therapeutics to address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules.

The company recently announced positive Phase 2 results for Oral NKTR-118, its proprietary novel peripheral opioid antagonist that combines Nektar's advanced small molecule polymer conjugate technology platform with naloxol, a derivative of the opioid-antagonist drug, naloxone. Nektar's technology has been shown to increase oral bioavailability and inhibit penetration across the blood-brain barrier, an important potential advance for small molecule therapies. The product is being developed to treat opioid-induced constipation (OIC).

NKTR-102, PEGylated irinotecan, is currently in Phase 2 clinical
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
3. Nektar Therapeutics Reports First Quarter 2009 Financial Results
4. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
5. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
6. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
7. Nektar Announces Retirement of Irwin Lerner from Board of Directors
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
9. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
10. Nektar Therapeutics to Webcast R&D Day on November 12th
11. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014 Yuma Regional ... and complementary therapies brings comprehensive cancer care to ... Yuma Regional Cancer Center has officially opened. A ... program includes services such as open, semi-private and ... American Cancer Society Resource Center, hematology, rehabilitation center, ...
(Date:7/30/2014)... July 30, 2014 Researchers often use ... biology, but such devices can do much more ... As such, researchers have looked to patterned assemblies ... metabolic engineering to characterize – and potentially ... devices are envisioned to recreate animal and human ...
(Date:7/30/2014)... , July 30, 2014  RXi Pharmaceuticals ... biotechnology company focused on discovering, developing and ... needs using RNA-targeted technologies, today announced that ... RXI-109, for the reduction of recurrence of ... has been initiated. Logo - ...
(Date:7/30/2014)... Diego, CA (PRWEB) July 30, 2014 ... contract from the U.S. Environmental Protection Agency (EPA). ... expertise in developmental toxicity models, including tests designed ... neuron formation and the formation of connections between ... Inhibition of neurodifferentiation and synapse formation by environmental ...
Breaking Biology Technology:Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3
... 10 Varian, Inc.,(NasdaqGS: VARI) announced the release ... applications involving liquid-state samples. The,OneNMR Probe product line ... a single probe rather than switching probes for,different ... and,research chemists performing a broad range of common ...
... TOKYO, and REDWOOD CITY, Calif., March 10, Otsuka ... PDLI ) today announced the closing of ... PDL,s,rights to IV Busulfex(R) (busulfan), including trademarks, patents,intellectual ... inventory,value., IV Busulfex is an oncologic product ...
... (Amex: PTN ) announced today the completion ... novel, long-acting natriuretic peptide,receptor A (NPRA) agonist under ... (CHF). The Phase I trial was a,randomized, double-blind, ... volunteers who received the medication or placebo,subcutaneously. The ...
Cached Biology Technology:Double Resonance Probe for Liquid State NMR Applications From Varian, Inc. Increases Productivity for Routine Analyses 2Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex 2Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex 3Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex 4Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 2Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 3Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 4
(Date:7/30/2014)... team of biologists, led by Clemson University associate professor ... pest that will pave the way for novel anti-fouling ... for medical and industrial applications. , The team,s findings, ... the last larval stage of barnacles that attaches to ... possibly polymeric material that acts as an underwater heavy-duty ...
(Date:7/30/2014)... today announced an across-the-board increase in Impact Factors ... InCites Journal Citation Reports (Thomson Reuters, 2014) show ... , Essays in Biochemistry , Biochemical ... all received increases in their Impact Factors. The ... published by Portland Press Limited. , 2014 Impact ...
(Date:7/30/2014)... professor from Wayne State University,s College of Engineering ... Science Foundation for the project, "Nanoparticle-directed synthesis of ... Science Foundation, nanotechnology is the creation and utilization ... properties and functions. A major bottleneck in scaling ... that connect different functional materials into one device. ...
Breaking Biology News(10 mins):Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2Across-the-board Impact Factor increases for Portland Press Limited 2NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... mean lighting more bush fires, ecologists have proposed. ... threatened by encroaching woodland that is destroying their habitat, ... and Stanford University (USA) has shown. "Broad-headed snakes ... km of Sydney, and those small communities are fast ...
... Over the past few years, honey bee keepers have experienced ... honey bee populations, causing some growers of fruits, nuts and ... the future. A new study published in the Annals ... bees, which are not affected by CCD, may serve as ...
... team of scientists from the National Institute of Oceanography ... expedition on research vessel Polarstern. The cooperative project Lohafex ... But it has dampened hopes on the potential of ... dioxide (CO 2 ) and thus mitigate global warming. ...
Cached Biology News:Australia's most endangered snake might need burning 2Wild bees can be effective pollinators 2Lohafex provides new insights on plankton ecology 2Lohafex provides new insights on plankton ecology 3Lohafex provides new insights on plankton ecology 4
APO-BrdU™ TUNEL Assay Kit *with Alexa Fluor® 488 anti-BrdU* *60 assays*...
The FlowTACS Apoptosis Detection Kit is designed specifically for in situdetection of apoptotic...
Recombinant Rat PTX2/SAP...
Request Info...
Biology Products: